128992-62-1

Upstream product

• 2252-51-9 2-choro-4-fluorobenzoic acid 
• 74-89-5 methylamine 
• 50-00-0 formaldehyd 
• 446-32-2 4-fluoroanthranilic acid 

Downstream Products

• 97927-92-9 7-fluoro-1-methyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione 
• 76568-02-0 flosequinan 
• 76568-68-8 flosequinoxan 
• 154639-75-5 1-(4-fluoro-2-methylaminophenyl)-2-methylsulfinylethanone 
• 915225-88-6 (4-Fluoro-2-methylamino-phenyl)-{3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone 

Relevant academic research and scientific papers

SELECTED BENZOFURAN DERIVATIVES

The invention relates to new benzofuran derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical

PHARMACEUTICAL COMPOUNDS

The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof for use in the treatment or prophylaxis of a disease state or condition mediated by protein kinase A and/or protein kinase B, wherein the ring Q is a benzene ring; J2-J1 is N=CR7 or R1aN-CO; G is OH or NR5R6; E is CONR7, NR7CO, C(R8)=C(R8) or (X)m(CR8R8a)n where X is O, S or NR7; provided that when J2-J1 is R1aN-CO, E is other than NR7CO; m and n are each 0 or 1, where m + n = 1 or 2; A is a bond and R4 and R4a are absent, or A is a saturated optionally substituted C1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between E and G, one carbon atom in the linker group A being optionally replaced by O or N; R1,Rla, R2, and R3 are each H; halogen; C1-6 hydrocarbyl optionally substituted by halogen, OH or C1-2 alkoxy; CN; CONHR8; NH2; NHCOR10 or NHCONHR10; R4 is H or C1-4 alkyl; R4a is H, C1-4 alkyl or a group R9; R5 and R6 are each selected from H, R9 and C1-4 hydrocarbyl optionally substituted by halogen, C1-2 alkoxy or R9;or NR5R6 forms a saturated 4-7 membered monocyclic heterocyclic group; R7 is H or C1-4 alkyl; R8 and R8a each H or saturated C1-4 hydrocarbyl optionally substituted by fluorine; R9is a monocyclic or bicyclic carbocyclic or heterocyclic group containing up to 3 ring heteroatoms selected from N, O and S; or R4, R4a and A together form a saturated monocyclic 4-7 membered heterocycle; or NR5R6, R4 and A form a saturated 4-7 membered monocyclic heterocycle; or R4,together with R7 or R8 and A and E form a 4-7 membered saturated monocyclic heterocycle; or NR5R6 and R7 or R8 together with A and E form a 4-7 membered saturated monocyclic heterocycle; and R10 is optionally substituted phenyl or benzyl.

Syntheses of Flosequinan: A Novel 4-Quinolone shown to be useful in Congestive Heart Failure

Two synthetic routes to flosequinan 1 and flosequinoxan 2 are described in which either ring closure of the β-keto sulfoxides 12 or 13 with ortho esters or cyclisation of the anilinoacrylates 23, 28 or 29 are the key steps.

5-fluoroanthranilic fungicides

Compounds of formula I STR1 where A is OH, B is H, C1-4 alkyl optionally substituted by C1-4 alkoxy carbonyl, C2-4 alkenyl, CONR2 or COR4 R1 is H, R2 is C1-4 alkyl, and R4 is C1-4 alkyl, or phenyl, optionally substituted by carboxy have pesticidal and especially fungicidal activity. Many of the compounds are novel and these compounds per se, form part of the invention.